Neuromuscular Disorders

Various Clinical Disturbances Precede MS Diagnosis

Various Clinical Disturbances Precede MS Diagnosis

Various clinical symptoms precede the diagnosis of multiple sclerosis by several years.

Eculizumab May Improve Independent Walking Ability in Guillain-Barré Syndrome

Eculizumab May Improve Independent Walking Ability in Guillain-Barré Syndrome

By

High-dose intravenous immunoglobulin therapy was administered to all patients and may have contributed to neutralization of eculizumab.

FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients

FDA Approves First Multiple Sclerosis Treatment for Pediatric Patients

By

The FDA's decision was based on data from the Phase 3 PARADIGMS study (N=215) which evaluated the safety and efficacy of oral fingolimod vs interferon beta-1a injection in pediatric patients aged 10 to <18 years with relapsing MS.

Linear Link for Physical Activity, Amyotrophic Lateral Sclerosis

Linear Link for Physical Activity, Amyotrophic Lateral Sclerosis

There is a linear correlation for physical activity with amyotrophic lateral sclerosis.

Online Fatigue Management Feasible, Effective for Multiple Sclerosis

Online Fatigue Management Feasible, Effective for Multiple Sclerosis

By

Investigators designed a parallel-group, 2-arm, randomized controlled trial to evaluate ELEVIDA, an online fatigue management program based on cognitive behavioral therapy and other therapy-based strategies.

Facioscapulohumeral Muscular Dystrophy Treatment Gets Fast Track Status

Facioscapulohumeral Muscular Dystrophy Treatment Gets Fast Track Status

By

ACE-083 is currently being studied in a Phase 2 trial for FSHD and another for Charcot-Marie-Tooth (CMT) disease.

Dimethyl Fumarate May Be Safe, Effective for Pediatric Multiple Sclerosis

Dimethyl Fumarate May Be Safe, Effective for Pediatric Multiple Sclerosis

By

Previous studies have shown that delayed-release DMF is safe and effective in treating RRMS in adult patients. The goal of this study was to extend these analyses to evaluate DMF in pediatric patients with RRMS.

Belimumab Nonsuperior to Placebo for Reducing Symptoms of Myasthenia Gravis

Belimumab Nonsuperior to Placebo for Reducing Symptoms of Myasthenia Gravis

By

The investigators suggest that the recruited participants may have reached a plateau in symptoms, which may have decreased the chances of additional improvement with belimumab treatment.

Primary Periodic Paralysis: Advice for Clinicians & Future Directions

Primary Periodic Paralysis: Advice for Clinicians & Future Directions

By

Neurology Advisor speaks with Annabelle Baughan, a retired hematologist-oncologist, and discusses her personal experience with Andersen-Tawil syndrome.

Efficacy of Disease-Modifying Drugs for Multiple Sclerosis May Decrease With Age

Efficacy of Disease-Modifying Drugs for Multiple Sclerosis May Decrease With Age

By

A regression model showed that efficacy of DMTs significantly decreased until age 53, after which disease progression is not affected by DMTs.

Ozanimod Superior to Interferon β-1a for Treatment of Relapsing Multiple Sclerosis

Ozanimod Superior to Interferon β-1a for Treatment of Relapsing Multiple Sclerosis

By

Researchers sought to compare the safety and efficacy of ozanimod vs interferon β-1a in individuals with relapsing multiple sclerosis.

Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy

Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy

By

The new guidelines focus on helping clinicians decide when to initiate, switch, or discontinue disease-modifying therapies for multiple sclerosis.

Are Vaccines Associated With Multiple Sclerosis Relapse?

Are Vaccines Associated With Multiple Sclerosis Relapse?

By

Researchers found there are no associations between vaccinations and multiple sclerosis relapse flares.

Cardiovascular Comorbidities Linked to Increased Brain Atrophy in Multiple Sclerosis

Cardiovascular Comorbidities Linked to Increased Brain Atrophy in Multiple Sclerosis

By

Researchers investigated the association between cardiovascular risk factors and the development of brain atrophy in individuals with multiple sclerosis.

Interaction of Alcohol, Smoking on Multiple Sclerosis Severity

Interaction of Alcohol, Smoking on Multiple Sclerosis Severity

By

A cross-sectional study aimed to assess the effect of smoking and alcohol consumption along with the interactions they have on the clinical course of multiple sclerosis.

Switching to Oral Fingolimod From Injectable Treatment Linked to Fewer MS Relapses

Switching to Oral Fingolimod From Injectable Treatment Linked to Fewer MS Relapses

By

As injectable disease-modifying therapies can be inconvenient for patients with MS, fingolimod offers an oral treatment option that is associated with significantly lower risk for relapse.

Occupational Exposure to Diesel Exhaust Tied to ALS Risk

Occupational Exposure to Diesel Exhaust Tied to ALS Risk

Researchers found that for men with any occupational exposure to diesel exhaust, the odds ratio for amyotrophic lateral sclerosis increased with increasing lag periods.

AAN: High Fish Intake Linked to Reduced Risk of Multiple Sclerosis

AAN: High Fish Intake Linked to Reduced Risk of Multiple Sclerosis

Compared with consuming fish less than once per month and no supplements, high fish intake was correlated with a significantly reduced risk of multiple sclerosis.

Scoliosis Surgery Found Beneficial for Cerebral Palsy Patients

Scoliosis Surgery Found Beneficial for Cerebral Palsy Patients

Scoliosis surgery in patients with cerebral palsy leads to a significant improvement in health-related quality of life.

Pinpointing Clinically Meaningful Change in Cervical Dystonia Treated With Botulinum Toxin

Pinpointing Clinically Meaningful Change in Cervical Dystonia Treated With Botulinum Toxin

By

The administration of treatment was performed over 5 treatment cycles, and the investigators assessed TWSTRS changes at baseline and 4 weeks following injection.

Pseudobulbar Affect Linked to Mood Symptoms in Parkinsonian Syndromes

Pseudobulbar Affect Linked to Mood Symptoms in Parkinsonian Syndromes

By

Pseudobulbar affect is characterized by episodes of inappropriate laughing or crying, and may be associated with increased anxiety and depression, as well as lower mental health status.

Riluzole Prolongs Survival in Late-Stage Amyotrophic Lateral Sclerosis

Riluzole Prolongs Survival in Late-Stage Amyotrophic Lateral Sclerosis

By

Patients who received 100 mg/day riluzole spent significantly more time in stage 4 than patients who were randomly assigned to placebo.

Firdapse NDA Submitted for Lambert-Eaton Myasthenic Syndrome

Firdapse NDA Submitted for Lambert-Eaton Myasthenic Syndrome

By

Results from the Phase 3 trial showed that the Quantitative Myasthenia Gravis (QMG) score at baseline to day 14 changed from 6.4 to 6.7 in the amifampridine group vs. 5.6 to 7.9 for the placebo group.

Primary Periodic Paralysis: A Physician's Personal Experience as a Patient

Primary Periodic Paralysis: A Physician's Personal Experience as a Patient

By

Neurology Advisor spoke with Annabelle Baughan, a retired hematologist-oncologist, who shared her personal experience with Andersen-Tawil syndrome.

First-in-Class Inhibitor Designated Orphan Drug for Spinal Muscular Atrophy

First-in-Class Inhibitor Designated Orphan Drug for Spinal Muscular Atrophy

By

By inhibiting the activation of myostatin, SRK-015 may promote a clinically meaningful increase in muscle mass and strength.

Improvement in Acute Optic Neuritis Similar With IV, Oral Corticosteroids

Improvement in Acute Optic Neuritis Similar With IV, Oral Corticosteroids

By

The advantages of oral prednisone include "being less expensive and more convenient to access and administer and [being] preferred by patients to [intravenous] methylprednisolone."

DMT Discontinuation in Older MS Patients: Clinical Outcomes Examined

DMT Discontinuation in Older MS Patients: Clinical Outcomes Examined

By

Of the total patients, 178 (29.7%) discontinued DMT during the study period with only 1 documented relapse occurring in the discontinuers.

Siponimod Reduces Disability Progression in Secondary Progressive Multiple Sclerosis

Siponimod Reduces Disability Progression in Secondary Progressive Multiple Sclerosis

By

Further research should focus on establishing whether siponimod exerts its effect on the pathogenic processes associated with disease progression or activity, or both.

Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis

Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis

By

The study was unable to verify whether the findings may be applicable for lesion locations other than those found with brain biopsies.

Evidence of Impaired Glucose Signaling in Amyotrophic Lateral Sclerosis

Evidence of Impaired Glucose Signaling in Amyotrophic Lateral Sclerosis

By

Further research is warranted to clarify the role played by insulin resistance in the pathogenesis of amyotrophic lateral sclerosis.

Sign Up for Free e-newsletters



CME Focus